HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Red Yeast Rice History Offers Blueprint For Clearing CBD As Dietary Ingredient

Executive Summary

Legal dispute between FDA and Pharmanex decided in 1999 could be precedent for using hemp-derived ingredients including CBD in supplements, even though CBD already has been authorized for clinical drug evaluation and for use in a drug, says attorney Miriam Guggenheim.

You may also be interested in...



US FDA's Decisions On 'Article' As Dietary Or Drug Ingredient: Level Playing Field?

FDA drug center could hold more sway over which ingredients are allowed for use in supplements than center regulating supplement industry, suggests CRN CEO Steve Mister at a recent regulatory conference. ODSP second-in-command Gregory Noonan allows that agency has “vague” rule for “article” used in a supplement or a drug.

EU Restricts Red Yeast Rice Supplements Over Safety Concerns

Restrictions on daily doses and mandatory label warnings now apply to dietary supplements containing monacolins from red yeast rice sold in the EU following long-running safety concerns about the substance.

Solving US Hemp Regulatory Problem Will Take Wider View Of FDA Rule – AHPA’s McGuffin

FDA, along with supplement and food industries, have looked to Congress to authorizing agency to waive exclusion rule for hemp ingredients. Instead, Michael McGuffin recommends amending DSHEA to clarify that the same ingredients at different concentrations can be allowed in supplements and drugs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS148848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel